We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Acacia Pharma Group Plc | LSE:0PNT | London | Ordinary Share | GB00BYWF9Y76 | ACACIA PHARM ORD SHS |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.00 | - |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMACPH Acacia Pharma Group plc Issue of Equity on Exercise of Options/Vesting of Performance Share Awards Cambridge, UK and Indianapolis, US -- 26 February 2021, 08:00 CET: Acacia Pharma Group plc ("Acacia Pharma", the "Group" or the "Company") (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces that application has been made to Euronext Brussels for the admission of the 24,500 Ordinary Shares of GBP0.02 each (the "New Ordinary Shares") to trading on Euronext Brussels ("Admission") to satisfy the exercise of options granted under the Company's Enterprise Management Incentive Share Option Plan. The New Ordinary Shares will rank pari passu in all respects with the Company's existing Ordinary Shares in issue. Following issue of the New Ordinary Shares, the Company's total issued share capital consists of 99,713,951 Ordinary Shares with one voting right per share. The Company does not hold any Ordinary Shares in Treasury. Therefore, following the issue of the New Ordinary Shares, the total number of voting rights in the Company is 99,713,951. Contacts Acacia Pharma Group plc International Media Mike Bolinder, CEO Mark Swallow, Frazer Hall, David Gary Gemignani, CFO Dible +44 1223 919760 / +1 317 505 1280 Citigate Dewe Rogerson IR@acaciapharma.com +44 20 7638 9571 acaciapharma@citigatedewerogerson.com US Investors Media in Belgium and the Netherlands LifeSci Advisors Chris Van Raemdonck Irina Koffler +32 499 58 55 31 +1 917-734-7387 chrisvanraemdonck@telenet.be ikoffler@lifesciadvisors.com Acacia Pharma Group plc The Officers' Mess, Royston Road, Duxford, Cambridge, CB22 4QH, United Kingdom Company number 9759376 www.acaciapharma.com
(END) Dow Jones Newswires
February 26, 2021 02:00 ET (07:00 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Acacia Pharma Chart |
1 Month Acacia Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions